Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Interest Expenses (2021 - 2025)

Historic Interest Expenses for Bicycle Therapeutics (BCYC) over the last 5 years, with Q3 2025 value amounting to $44000.0.

  • Bicycle Therapeutics' Interest Expenses rose 3333.33% to $44000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $201000.0, marking a year-over-year decrease of 9195.36%. This contributed to the annual value of $1.7 million for FY2024, which is 4698.13% down from last year.
  • According to the latest figures from Q3 2025, Bicycle Therapeutics' Interest Expenses is $44000.0, which was up 3333.33% from $54000.0 recorded in Q2 2025.
  • Over the past 5 years, Bicycle Therapeutics' Interest Expenses peaked at $883000.0 during Q2 2022, and registered a low of $33000.0 during Q3 2024.
  • Moreover, its 5-year median value for Interest Expenses was $818000.0 (2022), whereas its average is $603684.2.
  • As far as peak fluctuations go, Bicycle Therapeutics' Interest Expenses skyrocketed by 5670.5% in 2022, and later tumbled by 9594.59% in 2024.
  • Bicycle Therapeutics' Interest Expenses (Quarter) stood at $820000.0 in 2021, then increased by 0.73% to $826000.0 in 2022, then fell by 0.73% to $820000.0 in 2023, then plummeted by 93.66% to $52000.0 in 2024, then dropped by 15.38% to $44000.0 in 2025.
  • Its last three reported values are $44000.0 in Q3 2025, $54000.0 for Q2 2025, and $51000.0 during Q1 2025.